ArticleFrontiers in oncology2025
Predicting Ki-67 expression levels in non-small cell lung cancer using an explainable CT-based deep learning radiomics model.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Conventional chest CT features are associated with Ki-67 labeling index in lung adenocarcinoma: a single-center retrospective radiopathologic study.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To predict Ki-67 expression levels in non-small cell lung cancer (NSCLC) using an interpretable model combining clinical-radiological, radiomic, and deep learning features. Methods: This retrospective study included 259 NSCLC patients from Center 1 (training/validation sets) and 112 from Center 2 (independent test set). Patients were grouped by a 40% Ki-67 cutoff. Radiomic features and deep learning features were extracted from CT images, where the deep learning features were obtained via a deep residual network (ResNet18). The least absolute shrinkage and selection operator (LASSO) was used to select optimal features and compute radiomics (rad-score) and deep learning (deep-score) scores. Univariate and multivariate logistic regression were used to identify independent clinical-radiological predictors of Ki-67. Four support vector machine models were developed: a clinical-radiological model (based on independent clinical-radiological features), a radiomic model (using the rad-score), a deep learning model (using the deep-score), and a combined model (integrating all the above features). SHapley Additive exPlanations (SHAP) analysis was used to visualize feature contributions. Models' performance was assessed using receiver operating characteristic (ROC) curves and the integrated discrimination improvement (IDI) index. Results: High Ki-67 expression occurred in 76 (42.0%), 38 (48.7%), and 33 (29.5%) patients in the training, validation, and independent test sets, respectively. In the independent test set, the combined model achieved the highest predictive performance, with an AUC of 0.892 (95% CI: 0.828-0.956). This improvement over the clinical-radiological (0.820, 95% CI: 0.721-0.918), radiomics (0.750, 95% CI: 0.655-0.844), and deep learning (0.817, 95% CI: 0.732-0.902) models was statistically significant (all p<0.05), as supported by IDI values of 0.115, 0.288, and 0.095, respectively. SHAP analysis identified the deep-score, histological type, and rad-score as key predictors. Conclusion: The interpretable combined model can predict Ki-67 expression in NSCLC patients. This approach may provide imaging evidence to assist clinicians in optimizing personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.